255 related articles for article (PubMed ID: 38399608)
1. Current Role and Future Prospects of Positron Emission Tomography (PET)/Computed Tomography (CT) in the Management of Breast Cancer.
Robson N; Thekkinkattil DK
Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399608
[TBL] [Abstract][Full Text] [Related]
2. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
3. Artificial Intelligence in Breast Cancer: A Systematic Review on PET Imaging Clinical Applications.
Alongi P; Rovera G; Stracuzzi F; Popescu CE; Minutoli F; Arnone G; Baldari S; Deandreis D; Caobelli F
Curr Med Imaging; 2023; 19(8):832-843. PubMed ID: 36703586
[TBL] [Abstract][Full Text] [Related]
4. Present and future role of FDG-PET/CT imaging in the management of breast cancer.
Kitajima K; Miyoshi Y
Jpn J Radiol; 2016 Mar; 34(3):167-80. PubMed ID: 26733340
[TBL] [Abstract][Full Text] [Related]
5. Baseline FDG PET-CT imaging is necessary for newly diagnosed inflammatory breast cancer patients: a narrative review.
Patel MM; Le-Petross HT
Chin Clin Oncol; 2021 Dec; 10(6):56. PubMed ID: 34806397
[TBL] [Abstract][Full Text] [Related]
6. Impact of 18F-FDG PET/CT in the management decisions of breast cancer board on early-stage breast cancer.
Özdemir A; Güven M; Binici S; Uygur S; Toktaş O
Clin Transl Oncol; 2024 May; 26(5):1139-1146. PubMed ID: 37848693
[TBL] [Abstract][Full Text] [Related]
7. The lung cancers: staging and response, CT,
Owens C; Hindocha S; Lee R; Millard T; Sharma B
Br J Radiol; 2023 Aug; 96(1148):20220339. PubMed ID: 37097296
[TBL] [Abstract][Full Text] [Related]
8. Impact of
Dayes IS; Metser U; Hodgson N; Parpia S; Eisen AF; George R; Blanchette P; Cil TD; Arnaout A; Chan A; Levine MN
J Clin Oncol; 2023 Aug; 41(23):3909-3916. PubMed ID: 37235845
[TBL] [Abstract][Full Text] [Related]
9. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
[TBL] [Abstract][Full Text] [Related]
10. F-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography Has High Diagnostic Value for Pelvic and Distant Staging in Patients with High-risk Penile Carcinoma.
Ottenhof SR; Djajadiningrat RS; Versleijen MWJ; Donswijk ML; van der Noort V; Brouwer OR; Graafland NM; Vegt E; Horenblas S
Eur Urol Focus; 2022 Jan; 8(1):98-104. PubMed ID: 33685842
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting the accuracy of
Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
[TBL] [Abstract][Full Text] [Related]
12. MRI fused with prone FDG PET/CT improves the primary tumour staging of patients with breast cancer.
Garcia-Velloso MJ; Ribelles MJ; Rodriguez M; Fernandez-Montero A; Sancho L; Prieto E; Santisteban M; Rodriguez-Spiteri N; Idoate MA; Martinez-Regueira F; Elizalde A; Pina LJ
Eur Radiol; 2017 Aug; 27(8):3190-3198. PubMed ID: 28004161
[TBL] [Abstract][Full Text] [Related]
13. ¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer.
Groheux D; Cochet A; Humbert O; Alberini JL; Hindié E; Mankoff D
J Nucl Med; 2016 Feb; 57 Suppl 1():17S-26S. PubMed ID: 26834096
[TBL] [Abstract][Full Text] [Related]
14. The value of 18F-FDG PET/CT imaging in breast cancer staging.
Yararbas U; Avci NC; Yeniay L; Argon AM
Bosn J Basic Med Sci; 2018 Feb; 18(1):72-79. PubMed ID: 28763628
[TBL] [Abstract][Full Text] [Related]
15. Performance of FDG PET/CT in the clinical management of breast cancer.
Groheux D; Espié M; Giacchetti S; Hindié E
Radiology; 2013 Feb; 266(2):388-405. PubMed ID: 23220901
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET/CT for Primary Staging and Detection of Recurrence of Breast Cancer.
Groheux D
Semin Nucl Med; 2022 Sep; 52(5):508-519. PubMed ID: 35636977
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Role of Fluorodeoxyglucose PET in Breast Cancer: A History to Current Application.
Chakraborty D; Basu S; Ulaner GA; Alavi A; Kumar R
PET Clin; 2018 Jul; 13(3):355-361. PubMed ID: 30100075
[TBL] [Abstract][Full Text] [Related]
18. Assessment of whole-body MRI including diffusion-weighted sequences in the initial staging of breast cancer patients at high risk of metastases in comparison with PET-CT: a prospective cohort study.
Hottat NA; Badr DA; Ben Ghanem M; Besse-Hammer T; Lecomte SM; Vansteelandt C; Lecomte SL; Khaled C; De Grove V; Salem Wehbe G; Cannie MM; Jani JC
Eur Radiol; 2024 Jan; 34(1):165-178. PubMed ID: 37555959
[TBL] [Abstract][Full Text] [Related]
19. Advantages and limitations of FDG PET in the follow-up of breast cancer.
Lind P; Igerc I; Beyer T; Reinprecht P; Hausegger K
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S125-34. PubMed ID: 15085295
[TBL] [Abstract][Full Text] [Related]
20. Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning.
Jacene HA; DiPiro PJ; Bellon J; Hu J; Cheng SC; Warren L; Schlosnagle E; Nakhlis F; Rosenbluth JM; Yeh E; Overmoyer B
Breast Cancer Res Treat; 2020 Jun; 181(2):383-390. PubMed ID: 32318957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
